The in vivo metabolism of 4-bromo-2,5-dimethoxyphenethylamine (2C-B), a ring-substituted psychoactive phenethylamine, in the rat was studied. Male Wistar rats were administered 10 mg/kg of 2C-B hydrochloride orally, and 24 h urine fractions were collected. After enzymatic hydrolysis of the urine samples, the metabolites were extracted by liquld-liquid extraction and analyzed by gas chromatography-mass spectrometry. 2-(4-Bromo-2,5-dimethoxyphenyl)-ethanol, 4-bromo-2,5-dimethoxyphenylacetic acid, 2-(2.hydroxy-4-bromo-5-methoxyphenyl)-ethylamine, 2-(2-methoxy-4-bromo-5-hydroxyphenyl)-ethylamine, 1-acetoamino-2-(2-hydroxy-4-bromo-5-methoxyphenyl)-ethane, and 1-acetoamino-2-(2-methoxy-4-bromo-5-hydroxyphenyl).ethane were identified as 2C-B metabolites. These findings suggest that at least two metabolic pathways for 2C-B are operative in rats. The first pathway leads to the corresponding aldehyde metabolite by deamination, which is subsequently reduced or oxidized, to give the corresponding alcohol and carboxylic acid metabolites. The second pathway leads to the corresponding 2-O-desmethyl or 5-O-desmethyl metabolites in which the amino group is subsequently acetylated.
Introduction
4-Bromo-2,5-dimethoxyphenethylamine (2C-B, Figure 1 ), a ring-substituted phenethylamine, possesses psychoactive properties. 2C-B was first synthesized by Alexander Shulgin in 1974 and found to be psychoactive in 1975 (1) . In humans, 2C-B is active at doses between 4 and 30 mg, and within this range, the ingestion of 2C-B induces euphoria along with increased receptiveness of visual auditory, olfactory, and tacticle sensations. At a much higher dose, frightening hallucinations or an unexpectedly heavy trip may result (1, 2) . 2C-B appeared on the drug market in the 1980s as an MDMA replacement in the U.S. (3) , and during the 1990s 2C-B has become popular in some European countries such as the Netherlands and Switzerland (4, 5) . Reproduction (photocopyin 8) of editorial content of this journal is prohibited without publisher's permission.
Chemical synthesis of 2C-B and its metabolites
All synthesized standards were confirmed by chemical ionization mass spectrometry (CI-MS) and 1H NMR. CI-MS spectra were obtained from JEOL JMS-700T spectrometer (Akishima, Tokyo, Japan). Isobutane was used as reagent gas. 1H NMR spectra were measured on a JEOL JNM-ECP600 spectrometer. Tetramethylsilane was used as an internal standard.
2C-B hydrochloride (I).
This compound was synthesized in our laboratory using procedures described by Shulgin (2) .
CI-MS ra/z 260, 262 ([M+H] § ~H-NMR (CD3OD) 5 2.94 (2H, t, J=7.4 Hz), 3.14 (2H, t, ./=7.4 Hz), 3 .82 (3H, s), 3 .83 (3H, s), 6 .96 (1H, s), 7 .18 (1H, s).
2-(4-Bromo-2,5-dimethoxyphenyl)-ethanol (II).
To a wellstirred solution of 1 g of 2,5-dimethoxyphenylacetic acid in 20 mL of anhydrous tetrahydrofuran (THF) cooled on ice-bath, 2 g of lithium aluminum hydride was added, and the stirring continued for 15 rain. The mixture was then refluxed for 1 h. After the reaction mixture had cooled to room temperature, water was carefully added until the vigorous reaction ceased. The reaction mixture was filtered, and residual white solid was washed with THF and 3M hydrochloric acid. The filtrate was collected and THF evaporated under vacuum. The residual aqueous solution was extracted with dichloromethane and the solvent was evaporated to dryness under vacuum. The residue was 2-(2,5-dimethoxyphenyl)-ethanol (0.84 g).
To a well-stirred solution of 0.84 g of 2-(2,5-dimethoxyphenyl)-ethanol in 3 mL of acetic acid, 1 g of elemental bromine dissolved in 3 mL of acetic acid was added. After several minutes, the excess acetic acid was removed under vacuum. Water was added to the residue, and the mixture was made basic by the adding of a 5M sodium hydroxide solution, and then extracted with dichloromethane. After removing the solvent under vacuum, the residue was dissolved in 5 mL of a 1M sodium hydroxide/methanol solution. After stirring for 30 min at room temperature, water was added, the solution extracted with dichloromethane, and the solvent evaporated to dryness under vacuum. Recrystallization of the residue from 2-butanone/n-hexane gave 0.87 g of 2-(4-bromo-2,5-dimethoxyphenyl)-ethanol (II). 
4-Bromo-2,5-dimethoxyphenylacetic acid (III).
A 1-g sample of 2,5-dimehtoxyphenylacetic acid was brominated using a procedure similar to that used for the synthesis of compound II. Recrystallization of the crude product from 2-butanone/nhexane gave 0.8 g of 4-bromo-2,5-dimethoxyphenylacetic acid (III). 
2-(2-Hydroxy-4-bromo-5-methoxyphenyl)-ethylamine hydrochloride (IV).
To a solution of 2 g of 2-hydroxy-5-methoxybenzaldehyde in 20 mL of methanol, 0.8 g of sodium methoxide was added. The solvent was evaporated to dryness under vacuum, and 10 mL of dimethylformamide (DMF) and 3 mL of benzylchloride were added, after which the mixture was refluxed for 2 h. After the reaction mixture had cooled to room temperature, water wasadded, and the solution was made basic by the addition of a 5M sodium hydroxide solution and then extracted with diethylether. The extract was washed with water 10 times to remove the DMF, and the solvent was then evaporated to dryness under vacuum. A 3.4 g crude residue of 2-benzyloxy-5-methoxybenzaldehyde was obtained.
A solution of 3.4 g of 2-benzyloxy-5-methoxybenzaldehyde in 20 mL of nitromethane was treated with 0.2 g of anhydrous ammonium acetate and refluxed for 2 h. Excess nitromethane was removed under vacuum, water was added, and the mixture was extracted with dichloromethane. The solvent was evaporated to dryness under vacuum to give 3.7 g of 2-benzyloxy-5-methoxy-beta-nitrostyrene as yellow crystal.
A 3.7-g sample of 2-benzyloxy-5-methoxy-beta-nitrostyrene was reduced using lithium aluminum hydride using a procedure similar to that used for the synthesis of compound II, and crude 2-(2-benzyloxy-5-methoxyphenyl)-ethylamine was obtained. This crude product was brominated as described for compound II to give 2-(2-benzyloxy-4-bromo-5-methoxyphenyl)-ethylamine.
To a solution of 0.1 g of crude 2-(2-benzyloxy-4-bromo-5-methoxyphenyl)-ethylamine in 5 mL of acetic acid, 0.02 g of palladium-carbon (containing 5% palladium) was added, followed by vigorously stirring under hydrogen gas for 24 h. The catalyst was removed by filtration, and the solvent was evaporated to dryness under vacuum. The residue was dissolved in methanol, and hydrogen chloride gas was then bubbled through the solution to give the hydrochloride salt of the amine. The solvent was evaporated to dryness under vacuum, and recrystallization of the residue from methanol/diethylether gave 0.037 g of 2-(2-hydroxy-4-bromo-5-methoxyphenyl)-ethylamine hydrochloride (IV) as a brown powder. 
CI-MS

1-Acetoamino-2-(2-hydroxy-4-bromo-5-methoxyphenyl)-ethane (VI).
To a solution of 0.3 g of crude 2-(2-benzyloxy-4-bromo-5-methoxyphenyl)-ethylamine in 3 mL of THF, 0.5 mL of pyridine and 0.5 mL of acetic anhydride were added. After several minutes, water was added to the reaction mixture, the solution was acidified with 3M hydrochloric acid and then extracted with dichloromethane. After washing with 1M sodium hydroxide solution, the solvent was evaporated to dryness under vacuum. Crude 1-acetoamino-2-(2-benzyloxy-4-bromo-5-methoxyphenyl)-ethane was obtained as the residue.
This crude 1-acetoamino-2-(2-benzyloxy-4-bromo-5-methoxyphenyl)-ethane was debenzylated as described for compound IV. The crude product was purified by preparative thin-layer chromatography (TLC) to give 0.025 g of 1-acetoamino-2-(2-hydroxy-4-bromo-5-methoxyphenyl)-ethane (VI) as an amber oil. 
2-(2-Methoxy-4-bromo-5-hydroxyphenyl)-ethylamine hydrochloride (V).
To a solution of 10 g of 4-benzyloxyphenol and 20 g of sodium hydroxide in 12 mL of methanol, 50 mL of water was added, and the solution was then heated on a waterbath at 60-70~ To this solution, 20 mL of chloroform was added dropwise over a 1-h period and stirring was continued for an additional 30 min. The reaction mixture was cooled on an ice-bath, and 9M sulfuric acid was added until the solution became acidic. The resulting solution was extracted with diethylether, and the solvent was evaporated to dryness under vacuum. The residue was purified by silicagel column chromatography to give 4.8 g of 2-hydroxy-5-benzyloxybenzaldehyde as a white solid.
To a solution of 4.8 g of 2-hydroxy-5-benzyloxybenzaldehyde in 30 mL of methanol, 1.5 g of sodium methoxide was added. The solvent was evaporated to dryness under vacuum, 20 mL of DMF and 1.8 mL of methyl iodide were added, and the mixture was refluxed for 2 h. After the reaction mixture had cooled to room temperature, water was added, the solution was made basic by the addition of a 5M sodium hydroxide solution, and then extracted with diethylether. The solvent was washed with water 10 times, to remove the DMF, and the solvent was then evaporated to dryness under vacuum. A 4.5 g residue of 2-methoxy-5-benzyloxybenzaldehyde was obtained.
The subsequent reactions were performed by the same procedure as was used for the synthesis of compound IV. 
1-Acetoamino-2-(2-methoxy-4-bromo-5-hydroxyphenyl)-ethane (VII)
.
Drug administration and urine sampling
Four male Wistar rats were orally administered 10 mg/kg 2C-B hydrochloride and placed in metabolic cages. Urine samples were collected over 24 h and stored at-20~ until used for analysis.
Enzymatic hydrolysis
Enzymatic hydrolysis of the urine was performed by adding 1.25 mL of 0.5M acetate buffer (pH 5.0) and 15,000 units of ~-glucuronidase dissolved in 0.5 mL of 0.1M acetate buffer to 5 mL of urine, followed by incubation at 37~ for 48 h.
Extraction of the metabolites and sample preparation for
GC-MS
The procedure used for the extraction of the metabolites is summarized in Figure 2 . Hydrolyzed urine was acidified to pH 2 with 3M hydrochloric acid and then extracted with diethylether. The organic layer was back-extracted with a 0.1M sodium hydroxide solution. The organic layer was defined as fraction 1. The aqueous layer was acidified to pH 2 with 3M hydrochloric acid and again extracted with diethylether. This organic layer was defined as fraction 2. In addition, the remaining aqueous layer from the first extraction step was taken to pH 12 with 5M sodium hydroxide solution and extracted with chloroform. This organic layer was defined as fraction 3. The aqueous layer was neutralized by adding 3M hydrochloric acid, and the pH was then adjusted to about 9 by the addition of a 25% ammonium hydroxide solution and extracted with chloroform/isopropanol (3:1). This organic layer was defined as fraction 4. Each fraction was dried over anhydrous sodium sulfate and evaporated to dryness under vacuum. The residues of fraction I and fraction 2 were reconstituted in 1 mL of methanol for GC-MS analysis. The residues of fraction 3 and fraction 4 were reconstituted in I mL of methanol, and a 50-pL portion of each solution was transferred to another vial. The solvent was evaporated to dryness under a gentle stream of nitrogen. The residue was dissolved in 50 pL of THF containing 10% pyridine and 10% isobutyric anhydride for GC-MS analysis. 
GC-MS analyses were performed using a JEOL JMS-700T equipped with a DB-5ms capillary column (30 m x 0.32-mm i.d., 0.25-pro film thickness, J&W Scientific, Folsom, CA). The oven temperature was held at 80~ for I rain following injection and programmed to 280~ at rate of 15~
The injection port and interface temperature were 250~ and 280~ respectively. Helium was used as carrier gas at a flow rate of I mL/min. The MS was operated in the electron ionization (EI) mode and the chemical ionization (CI) mode with a reagent gas of isobutane at an ionization energy of 70 eV. Samples were injected in the splitless mode.
Results and Discussion
Four fractions were obtained from the hydrolyzed urine by liquid-liquid extraction, and each fraction was analyzed by GC-MS under both EI and CI modes. Because 2C-B and its metabolites contain bromine, typical bromine isotope peaks in the mass spectrum were used as a suitable target to search for the metabolites of 2C-B. Figure 3 shows the total ion chromatogram (TIC) under the EI mode obtained from fraction 1. The neutral compounds are included in this fraction. The EI and CI mass spectra of peak A are shown in Figure 4 . The ions at m/z 260 and 229 in the EI mass spectrum ( Figure 4A ) have characteristic isotopic ions of m/z 262 and 231, respectively, with the same relative intensity, suggesting that this molecule contains one bromine atom. Because a protonated molecular ion [M+H] § was observed at m/z 261 (and 263) in the CI mass spectrum (Figure 4B) , the ion at m/z 260 (262) in EI mass spectrum was assumed to be a molecular ion, and a fragment ion at m/z 229 (231) was assumed to be a [~-cleavage fragment derived from the side chain. Therefore, peak A was presumed to be the corresponding alcohol metabolite (II). This was confirmed by a comparison of the retention time and the mass spectra of peak A with those obtained from the synthetic reference standard for compound II. Figure 5 shows the TIC under the EI mode obtained from fraction 2. The acidic compounds are included in this fraction. The EI and CI mass spectra of peak B was shown in Figure 6 . Peak B was presumed to be the corresponding carboxylic acid metabolite (III) because ions at m/z 274 (276) and 229 (231) were consistent with a molecular ion and a decarboxylated fragment ion, respectively. This was also confirmed by a comparison of the retention time and the mass spectra of peak B with those obtained from the synthetic reference compound.
The EI and CI mass spectra of peak C and peak D are shown in Figures 7 and 8 , respectively. Characteristic ions at m/z 287 (289), 228 (230), and 213 (215) were observed in both of the EI mass spectra ( Figures 7A and 8A ) with similar relative intensity, suggesting that these two molecules are structurally similar. Protonated molecular ions [M+H] + were observed at m/z 288 (290) in both of the CI mass spectra (Figures 7B and 8B ). Because the compounds in this fraction possess acid properties, and the ion at m/z 228 (230) is formed by loss of NH--C(OH) CH3, peak C and peak D were presumed to be the O-desmethyl- N-acetyl metabolites. By a comparison of the retention times and the mass spectra of peaks C and D with those of the synthetic reference standards, peak C and peak D were identified as 5-O-desmethyl-N-acetyl metabolite (VII) and 2-O-desmethyl-Nacetyl metabolite (VI), respectively.
The TIC under the EI mode obtained from the iso-butyrylderivative of fraction 3 is shown in Figure 9 . The basic compounds are included in this fraction. The EI and CI mass spectra of peak E are shown in Figure 10 . This peak was presumed to be the iso-butyryl-derivative of unchanged 2C-B because the ions at m/z 329 (331) and 242 (244) were consistent with a molecular ion and a fragment ion produced by the loss of NH=C(OH)CH(CH3)2, respectively. This was confirmed by a comparison of the retention time and the mass spectra of peak E with those obtained from the iso-butyryl-derivative of 2C-B.
The TIC under the EI mode obtained from the iso-butyrylderivative of fraction 4 is shown in Figure 11 . Compounds that contain both phenolic and amino groups are included in this fraction. The EI and CI mass spectra of peak F and peak G are shown in Figures 12 and 13 , respectively. These two peaks were presumed to be the N,O-di-iso-butyryl derivatives of the Odesmethyl metabolites of 2C-B because the ion at m/z 315 (317) is formed by loss of (CH3)2C=C=O and ion at m/z 228 (230) is formed by the loss of (CH3)2C=C=O and NH=C(OH)CH(CH3)2. A comparison of the retention times and the mass spectra of peaks F and G with those obtained from the iso-butyryl-derivative of synthetic reference compounds, indicates that peaks F and G are 2-O-desmethyl (IV) and 5-0-desmethyl metabolites (V), respectively.
From these results, two metabolic pathways for 2C-B in the rat can be postulated, as shown in Figure 14 . The first pathway leads to the corresponding aldehyde metabolite by deamination, which is subsequently reduced or oxidized to form the corresponding alcohol and carboxylic acid metabolites (II and III). The intermediate aldehyde4orm metabolite was not detected in urine, suggesting that it is rapidly converted to the alcohol or carboxylic acid metabolite. The second pathway leads to the O-desmethyl metabolites (IV and V) by O-demethylation, the amino groups of which are subsequently acetylated to form the O-desmethyl-N-acetyl metabolites (VI and VII).
It is known that some [3-substituted ethylamines, such as serotonin, histamine, and mescaline, are also metabolized to the corresponding carboxylic acid and N-acetyl metabolites (7, 8) . The results in this study indicate that the metabolic pathways of 2C-B are similar to those of these amines.
A preliminary quantitation of each metabolite indicated that O-desmethyl-N-acetyl metabolites (VI and VII) are major metabolites, whereas a small amount of unchanged 2C-B is excreted in urine. A quantitative evaluation of these seven metabolites of 2C-B including parent compound is currently in progress, and the result will be published in a later report.
